Antibody that binds to envelope glycoprotein of sever fever with thrombocytopenia syndrome virus and use for same

Abstract

The present invention relates to an antibody which specifically binds to the envelope glycoprotein of severe fever with thrombocytopenia syndrome virus (SFTSV), the pathogen of severe fever with thrombocytopenia syndrome (SFTS), and is used in order to effectively detect or diagnosis SFTSV and treat SFTS.

1 .- 19 . (canceled) 
     
     
         20 . An antibody which specifically binds to Gc that is an envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, wherein the antibody comprises
 a) a light chain complementarity determining region 1 (LCDR1) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 21, 22, 23, 24 and 25,   b) a light chain complementarity determining region 2 (LCDR2) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 41, 42, 43, 44 and 45,   c) a light chain complementarity determining region 3 (LCDR3) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 61, 62, 63, 64 and 65,   d) a heavy chain complementarity determining region 1 (HCDR1) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 26, 27, 28, 29 and 30,   e) a heavy chain complementarity determining region 2 (HCDR2) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 46, 47, 48, 49 and 50, and   f) a heavy chain complementarity determining region 3 (HCDR3) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 66, 67, 68, 69 and 70.   
     
     
         21 . The antibody according to  claim 20 , wherein the antibody comprises
 a light chain comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4 and 5, and   a heavy chain comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 6, 7, 8, 9 and 10.   
     
     
         22 . The antibody according to  claim 20 , wherein the antibody comprises
 a light chain comprising a sequence having 95% or more of sequence identity to any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4 and 5, and   a heavy chain comprising a sequence having 95% or more of sequence identity to any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 6, 7, 8, 9 and 10.   
     
     
         23 . An antibody which specifically binds to Gn that is an envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, wherein the antibody comprises
 a) a light chain complementarity determining region 1 (LCDR1) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 101, 102, 103, 104 and 105,   b) a light chain complementarity determining region 2 (LCDR2) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 121, 122, 123, 124 and 125,   c) a light chain complementarity determining region 3 (LCDR3) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 141, 142, 143, 144 and 145,   d) a heavy chain complementarity determining region 1 (HCDR1) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 106, 107, 108, 109 and 110,   e) a heavy chain complementarity determining region 2 (HCDR2) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 126, 127, 128, 129 and 130, and   f) a heavy chain complementarity determining region 3 (HCDR3) comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 146, 147, 148, 149 and 150.   
     
     
         24 . The antibody according to  claim 23 , wherein the antibody comprises
 a light chain comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 81, 82, 83, 84 and 85, and   a heavy chain comprising any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 86, 87, 88, 89 and 90.   
     
     
         25 . The antibody according to  claim 23 , wherein the antibody comprises
 a light chain comprising a sequence having 95% or more of sequence identity to any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 81, 82, 83, 84 and 85, and   a heavy chain comprising a sequence having 95% or more of sequence identity to any one of amino acids sequence selected from the group consisting of SEQ ID NOs: 86, 87, 88, 89 and 90.   
     
     
         26 . A nucleic acid comprising at least one of
 a) a nucleotide sequence encoding a polypeptide comprising a sequence having 95% or more of sequence identity to any one of amino acids selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4 and 5, and a nucleotide sequence encoding a polypeptide comprising a sequence having 95% or more of sequence identity to any one of amino acids selected from the group consisting of SEQ ID NOs: 6, 7, 8, 9 and 10; and   b) a nucleotide sequence encoding a polypeptide comprising a sequence having 95% or more of sequence identity to any one of amino acids selected from the group consisting of SEQ ID NOs: 81, 82, 83, 84 and 85, and a nucleotide sequence encoding a polypeptide comprising a sequence having 95% or more of sequence identity to any one of amino acids selected from the group consisting of SEQ ID NOs: 86, 87, 88, 89 and 90.   
     
     
         27 . A vector comprising the nucleic acid of  claim 26 . 
     
     
         28 . A host cell comprising the vector of  claim 27 . 
     
     
         29 . A composition for diagnosing or detecting SFTSV comprising the antibody of  claim 20 . 
     
     
         30 . A kit for diagnosing or detecting SFTSV comprising the antibody of  claim 20 . 
     
     
         31 . A method for diagnosing or detecting SFTSV using the antibody of  claim 20 . 
     
     
         32 . The method according to  claim 31 , wherein the method uses a complex in which the antibody and a magnetic bead are bound. 
     
     
         33 . A pharmaceutical composition comprising the antibody of  claim 20 . 
     
     
         34 . A method for preventing or treating SFTS using the antibody of claim  claim 20 .